Details of Disease

General Information of Disease (ID: DISRNAI4)

Disease Name Human immunodeficiency virus infection
Disease Class 1C60-1C62: Human immunodeficiency virus disease
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISRNAI4: Human immunodeficiency virus infection
ICD Code
ICD-11
ICD-11: 1C62
Disease Identifiers
MESH ID
D015658
MedGen ID
5583
SNOMED CT ID
86406008

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 45 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Abacavir DMMN36E Approved Small molecular drug [1]
Acemannan DMMG1VO Approved Small molecular drug [2]
Amprenavir DMLMXE0 Approved Small molecular drug [3]
Atazanavir DMSYRBX Approved Small molecular drug [4]
Bictegravir, emtricitabine and tenofovir alafenamide DMG0H8K Approved NA [5]
Cobicistat DM6L4H2 Approved Small molecular drug [6]
Darunavir DMN3GCH Approved Small molecular drug [4]
Delavirdine DM3NF5G Approved Small molecular drug [7]
Didanosine DMI2QPE Approved Small molecular drug [8]
Dolutegravir DMCZGRE Approved Small molecular drug [9]
Efavirenz DMC0GSJ Approved Small molecular drug [7]
Elvitegravir DMG9B1U Approved Small molecular drug [10]
Emtricitabine DMBMUWZ Approved Small molecular drug [11]
Enfuvirtide DM7YPM1 Approved Small molecular drug [12]
Fosamprenavir DM4W9B3 Approved Small molecular drug [7]
Fostemsavir DM50ILT Approved Small molecular drug [13]
Gepon DMQ10KG Approved NA [2]
Glutathione DMAHMT9 Approved Small molecular drug [14]
GS-7340 DM1ECNJ Approved Small molecular drug [15]
H5N1 influenza vaccine DMMHYLB Approved Vaccine [16]
Ibalizumab DMV67QO Approved Antibody [5]
Indinavir DM0T3YH Approved Small molecular drug [7]
Interferon alfa-n3 DMTZNQ9 Approved NA [17]
IRT-103 DMVOXO0 Approved NA [18]
Lamivudine DMI347A Approved Small molecular drug [4]
Lenacapavir DMW7TZV Approved Small molecular drug [19]
Lopinavir DMITQS0 Approved Small molecular drug [4]
Maraviroc DMTL94F Approved Small molecular drug [20]
MK-1439 DM215WE Approved Small molecular drug [5]
Motexafin gadolinium DMEJKRF Approved Small molecular drug [21]
Naltrexone DMUL45H Approved Small molecular drug [22]
Nevirapine DM6HX9B Approved Small molecular drug [7]
Oxothiazolidine carboxylate DMROCUP Approved NA [2]
Penciclovir DMOUMDV Approved Small molecular drug [4]
Pentamidine DMHZJCG Approved Small molecular drug [2]
Raltegravir DMYURI6 Approved Small molecular drug [23]
Rilpivirine DMJ0QOW Approved Small molecular drug [24]
Ritonavir DMU764S Approved Small molecular drug [4]
Saquinavir DMG814N Approved Small molecular drug [25]
Stavudine DM6DEK9 Approved Small molecular drug [4]
Tenofovir DM1IS6U Approved Small molecular drug [26]
Tipranavir DM8HJX6 Approved Small molecular drug [4]
Zalcitabine DMH7MUV Approved Small molecular drug [27]
Zidovudine DM4KI7O Approved Small molecular drug [28]
Zinc Acetate DM3X357 Approved Small molecular drug [29]
------------------------------------------------------------------------------------
⏷ Show the Full List of 45 Drug(s)
This Disease is Treated as An Indication in 182 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
AIDSVAX DMS2WV3 Phase 3 Vaccine [30]
Albuvirtide DMZ7BCQ Phase 3 Small molecular drug [31]
AMD-070 DMVOY6B Phase 3 Small molecular drug [32]
Apricitabine DM1K78U Phase 3 Small molecular drug [33]
E-913 DMUHS5Q Phase 3 Small molecular drug [34]
GSK1265744 DMT8J0I Phase 3 Small molecular drug [35]
H5N1 influenza vaccine DM9O32B Phase 3 NA [36]
MK-8591 DMT6IRI Phase 3 NA [37]
PC-213 DMPOVPQ Phase 3 NA [38]
Pixykine DMCA6BW Phase 3 NA [39]
PRo antigen cancer vaccine DMTG6N1 Phase 3 NA [40]
PRO-140 DMD1FTP Phase 3 NA [41]
PRO-2000 DMYNA1C Phase 3 Small molecular drug [42]
Remune DMFLECG Phase 3 NA [43]
Rintatolimod DMYX7VI Phase 3 Protein/peptide drug [44]
Rubitecan DMDWU1S Phase 3 Small molecular drug [45]
Sifuvirtide DMMIWCE Phase 3 NA [46]
TNX-355 DMYA41S Phase 3 NA [47]
VAC89220 DMNMFBE Phase 3 Vaccine [48]
Vicriviroc DMMTW9K Phase 3 Small molecular drug [49]
ALVAC-HIV DMKUT8Z Phase 2/3 Vaccine [50]
VM-1500 DM4WQBO Phase 2/3 NA [51]
INCB9471 DMMWC6F Phase 2a Small molecular drug [52]
ALT-803 DMK3U1X Phase 2 NA [41]
ALX-40-4C DMV934L Phase 2 Small molecular drug [53]
APH-0812 DM756GE Phase 2 NA [41]
Bevirimat DML2D8Q Phase 2 Small molecular drug [54]
BILR-355 DMAG4SX Phase 2 NA [55]
Cenicriviroc DM4V8WF Phase 2 Small molecular drug [56]
CYT107 DMUWDED Phase 2 NA [57]
DG-17 DMS9Y1T Phase 2 NA [58]
Elsulfavirine DM73D90 Phase 2 NA [41]
EMIVIRINE DMQH1NV Phase 2 Small molecular drug [59]
F4co vaccine DM6UQNW Phase 2 Vaccine [60]
FIT-06 DMCKZG7 Phase 2 NA [61]
GOVX-B11 DMWR17P Phase 2 NA [62]
GS-9620 DMG5C8D Phase 2 Small molecular drug [41]
GSK-706769 DMPLKAH Phase 2 NA [63]
GSK3640254 DMMOWT9 Phase 2 NA [64]
GTU-based DNA vaccine DM3AOX7 Phase 2 NA [65]
HGTV43 DM0LA6E Phase 2 Antisense drug [66]
HIV recombinant proteins vaccine DMCESM2 Phase 2 NA [67]
HIV recombinant vaccine DMSJSD1 Phase 2 NA [68]
HIV vaccines DM95CVL Phase 2 NA [69]
HPH-116 DM3WSL2 Phase 2 NA [70]
IDX899 DMSRC5D Phase 2 Small molecular drug [71]
IRT-101 DM7UEKT Phase 2 NA [41]
ISCAR DM58LOX Phase 2 NA [72]
ITV-1 DMCJX79 Phase 2 Vaccine [73]
KNI-272 DMQZ5HF Phase 2 Small molecular drug [74]
KP-1461 DMG02ET Phase 2 Small molecular drug [75]
L-697,661 DMB7WT1 Phase 2 Small molecular drug [76]
Lersivirine DMSEVBH Phase 2 Small molecular drug [77]
Lexgenleucel-T DMNH6GP Phase 2 NA [78]
LIPO-5 DMWY0V1 Phase 2 Vaccine [79]
LTB4 DME26RS Phase 2 Small molecular drug [80]
MVA62B DMWIQUH Phase 2 NA [81]
NOV-205 DM7LOZF Phase 2 NA [82]
PF-232798 DM8T6KQ Phase 2 Small molecular drug [83]
POL-6326 DM4OT29 Phase 2 NA [84]
PTX-111 DM9SNY3 Phase 2 NA [85]
RALURIDINE DMBFZSX Phase 2 Small molecular drug [86]
RAP101 DM66GOT Phase 2 NA [87]
RFT-5.dgA DMQ8K93 Phase 2 NA [88]
Ro-24-7429 DMA2UYE Phase 2 Small molecular drug [89]
S-1360 DM9KTSG Phase 2 Small molecular drug [90]
S-364735 DMU7ZMH Phase 2 NA [91]
SB-728-T DMRWE5D Phase 2 NA [41]
TgAAC-09 DMJP6EJ Phase 2 NA [92]
TMC-310911 DMW145U Phase 2 NA [93]
VAX-125 DMR57OZ Phase 2 NA [94]
VH3810109 DM0LALF Phase 2 Antibody [95]
VRC-HIVADV014-00-VP DM8BNWK Phase 2 NA [96]
VRC-HIVDNA016-00-VP DMHET8R Phase 2 Vaccine [96]
VRX806 DMRLQYZ Phase 2 Small molecular drug [97]
Ad35-GRIN DM4L28K Phase 1/2 Vaccine [98]
AMZ-0026 DMIUP2E Phase 1/2 NA [99]
Anti-HIV ribozyme therapy DMQZJ3B Phase 1/2 NA [100]
Dapivirine DMJPSIL Phase 1/2 Small molecular drug [101]
DdRNAi therapy rHIV7-shl-TAR-CCR5RZ, stem cells DM0I5LM Phase 1/2 RNAi therapeutics [102]
DNA-C DM2A5IH Phase 1/2 NA [41]
HIV vaccine DMBD5O6 Phase 1/2 NA [103]
IFN alpha kinoid DMLEVFW Phase 1/2 NA [104]
M87o DMN2GU1 Phase 1/2 NA [105]
MVA-BN HIV Multiantigen DMZI75R Phase 1/2 NA [106]
PENNVAX-GP/MVA-CMDR HIV vaccine regime DM6ZF9Y Phase 1/2 NA [107]
SB-728-HSPC DMO8KUV Phase 1/2 NA [41]
T-1249 DMB2NP8 Phase 1/2 Small molecular drug [108]
Vacc-5q DMSH2CY Phase 1/2 NA [109]
Vacc-C5 DMEMYRO Phase 1/2 NA [110]
VIR-201 DMAMIU4 Phase 1/2 NA [111]
VIR-576 DM6JCR1 Phase 1/2 Small molecular drug [112]
Acriflavine DMKVE8X Phase 1 Small molecular drug [113]
Ad26.ENVA.01 HIV-1 recombinant vaccine DMZP3XI Phase 1 NA [114]
Ad35-GRIN/ENV DMG82ZA Phase 1 Vaccine [115]
ADVAX DMH8Z9W Phase 1 NA [116]
AIC-292 DMNHBMC Phase 1 NA [117]
ATEVIRDINE DM96JTX Phase 1 Small molecular drug [118]
ATI-0917 DMT5Z84 Phase 1 NA [119]
BG-777 DM377LN Phase 1 NA [120]
BI-224436 DM3UYNR Phase 1 NA [121]
C-2507 DMOFT1V Phase 1 Small molecular drug [122]
Capravirine DM9ERH1 Phase 1 Small molecular drug [123]
CCR5 mab DMCFMHR Phase 1 Antibody [124]
Clade A HIV vaccine DMXYV07 Phase 1 NA [41]
Clade B HIV vaccine DM5YHF3 Phase 1 NA [41]
Clade C HIV vaccine DMNVQW5 Phase 1 NA [41]
Clade D HIV vaccine DMYI283 Phase 1 NA [41]
CMX-157 DMMF0J3 Phase 1 Small molecular drug [125]
CN54gp140-hsp70 conjugate vaccine DM356J6 Phase 1 NA [126]
Combinectin DMTLP1N Phase 1 NA [127]
CTP-298 DMIKX01 Phase 1 NA [128]
DCVax-001 DMC54OI Phase 1 NA [129]
DNA-HIV-C/NYVAC-HIV-C DM197R2 Phase 1 NA [130]
DNA/MVA HIV vaccine DMKOQET Phase 1 NA [131]
DP-6001 DMM28OM Phase 1 NA [132]
Drug 2838232 DM0DJPE Phase 1 NA [133]
Edurant LA DMQ5R25 Phase 1 NA [41]
Elipovimab DMHC2V1 Phase 1 Antibody [134]
EP HIV-1090 vaccine DMREGCT Phase 1 NA [135]
Gp41 HIV-1 vaccine DM9JV80 Phase 1 NA [136]
GS-1156 DMDO6W4 Phase 1 Small molecular drug [134]
GS-2872 DMJDRVB Phase 1 Antibody [137]
GS-5423 DM9JQTQ Phase 1 Antibody [137]
GW-695634 DMBDW93 Phase 1 NA [138]
H5N1 influenza vaccine DMRSAZI Phase 1 NA [139]
HIV gp41 vaccine DMVM2H9 Phase 1 NA [136]
HIV MAG pDNA vaccine DMMT73D Phase 1 Vaccine [140]
HIV vaccine DMSP9Q1 Phase 1 NA [141]
HIV vaccine DMV4U2Y Phase 1 NA [142]
HIV vaccine DMVI9BB Phase 1 NA [143]
HIV vaccine DMWA4DW Phase 1 NA [144]
HIV vaccine DMX48DF Phase 1 NA [145]
HIV vaccine Ad4-Clade C DMEDVBO Phase 1 NA [67]
HIV vaccine Ad4-mGag DMQUIES Phase 1 NA [41]
HIVAX DMW3YKB Phase 1 NA [67]
IHV001 DMF4FBQ Phase 1 NA [41]
INCB15050 DMW7CLY Phase 1 NA [146]
KM-023 DME8DUV Phase 1 NA [147]
Leukocyte interleukin DM2B0TJ Phase 1 NA [148]
LFn-p24 DM7ZYPE Phase 1 NA [149]
LFn-p24-B-C DMBJVRI Phase 1 NA [149]
LIPO-4 DMJRALD Phase 1 Vaccine [150]
MB-66 DMY3K8I Phase 1 Antibody [41]
MEDI-550 DMWEXYK Phase 1 NA [151]
MK-6186 DMSA27Z Phase 1 Small molecular drug [152]
MRKAd5/ALVAC DM30P2H Phase 1 NA [153]
mRNA-1574 DM451AT Phase 1 Vaccine [154]
MSH-372 DMEP7HO Phase 1 Small molecular drug [155]
Multi-envelope HIV vaccine DMAGCHE Phase 1 Vaccine [156]
N-803 DM4ZN8M Phase 1 Recombinant protein [157]
PBSVax DMMR4E7 Phase 1 NA [158]
PC-1005 DM75Z21 Phase 1 NA [155]
PENNVAX-6 DM0BNLC Phase 1 NA [159]
Pennvax-B DMUTISK Phase 1 Vaccine [160]
Pennvax-G DM7YX8G Phase 1 Vaccine [161]
PEP-6409 DM7UM3E Phase 1 NA [145]
PF-03716539 DMW6Y6N Phase 1 NA [162]
PF-04776548 DMLGD0V Phase 1 NA [163]
PPL-100 DMOYUPM Phase 1 Small molecular drug [41]
Recombinant Tat protein vaccine DM25EMM Phase 1 NA [164]
RPI-MN DM5OXPZ Phase 1 NA [41]
RVSVIN HIV-1 gag vaccine DMYRPC8 Phase 1 Vaccine [165]
S-265744 LAP DMDQRWT Phase 1 NA [166]
S-648414 DM9L0IZ Phase 1 NA [167]
SAR441236 DMZ0XWE Phase 1 Antibody [168]
SPC-3 DMHNDW5 Phase 1 Small molecular drug [169]
SPI-452 DM506B6 Phase 1 NA [170]
SPL-7013 DM6SIFQ Phase 1 NA [171]
TBC-M4 DM9CDPO Phase 1 Vaccine [116]
TROVIRDINE HYDROCHLORIDE DMDSF0Q Phase 1 Small molecular drug [172]
UC-781 DM5XMHB Phase 1 Small molecular drug [173]
V520/V526 combination vaccine DMR62ZD Phase 1 NA [174]
VCH-286 DMMKUOZ Phase 1 NA [175]
VH3739937 DM2E1V5 Phase 1 NA [176]
VH4004280 DMM5L3S Phase 1 NA [177]
VH4011499 DM1GSSM Phase 1 NA [178]
VH4524184 DM1FS0F Phase 1 NA [179]
VRC-HIVADV027-00-VP DMM1J98 Phase 1 NA [180]
VRC01LS DMCSYSR Phase 1 NA [41]
Z-100 DM1H75D Phase 1 NA [181]
Gca-186 DMNH6F5 Clinical trial Small molecular drug [182]
------------------------------------------------------------------------------------
⏷ Show the Full List of 182 Drug(s)
This Disease is Treated as An Indication in 84 Patented Agent(s)
Drug Name Drug ID Highest Status Drug Type REF
1,2,4-oxadiazole derivative 1 DMESOA8 Patented Small molecule immunotherapy [183]
1,2,4-oxadiazole derivative 2 DMA42SB Patented Small molecule immunotherapy [183]
1,2,4-oxadiazole derivative 4 DMT6EDP Patented Small molecule immunotherapy [183]
1,2,4-oxadiazole derivative 5 DM683R7 Patented Small molecule immunotherapy [183]
1,2,4-oxadiazole derivative 6 DMFYKBJ Patented Small molecule immunotherapy [183]
1,2,4-oxadiazole derivative 7 DMBT4RJ Patented Small molecule immunotherapy [183]
1,3,4-oxadiazole derivative 1 DMJMCNP Patented Small molecule immunotherapy [183]
1,3,4-oxadiazole derivative 2 DMH26EO Patented Small molecule immunotherapy [183]
1,3,4-oxadiazole derivative 3 DMSR0X6 Patented Small molecule immunotherapy [183]
1,3,4-oxadiazole derivative 4 DM4GR2C Patented Small molecule immunotherapy [183]
1,3,4-oxadiazole derivative 5 DMI5VZN Patented Small molecule immunotherapy [183]
1,3,4-oxadiazole derivative 6 DMIEZ6L Patented Small molecule immunotherapy [183]
1,3,4-thiadiazole derivative 1 DMAB8QF Patented Small molecule immunotherapy [183]
1,3,4-thiadiazole derivative 2 DMXIG07 Patented Small molecule immunotherapy [183]
1,3-dihydroxy phenyl derivative 1 DMUS7O3 Patented Small molecule immunotherapy [183]
1,3-dihydroxy phenyl derivative 2 DM63NX5 Patented Small molecule immunotherapy [183]
3-substituted-1,2,4-oxadiazole derivative 1 DMWCT04 Patented Small molecule immunotherapy [183]
3-substituted-1,2,4-oxadiazole derivative 2 DMB3806 Patented Small molecule immunotherapy [183]
Aromatic acetylene derivative 1 DMGR6X1 Patented Small molecule immunotherapy [183]
Aromatic ethylene derivative 1 DMSRKON Patented Small molecule immunotherapy [183]
Benzyl phenyl ether derivative 1 DM6PTOX Patented Small molecule immunotherapy [183]
Benzyl phenyl ether derivative 2 DMMS4EI Patented Small molecule immunotherapy [183]
Biaryl compound 1 DMHEAJQ Patented Small molecule immunotherapy [183]
Biaryl compound 2 DMS8VYE Patented Small molecule immunotherapy [183]
Bromo benzyl ether derivative 1 DMMXQJU Patented Small molecule immunotherapy [183]
Bromo benzyl ether derivative 2 DMVBAUC Patented Small molecule immunotherapy [183]
Cyclic compound 1 DMSVMUT Patented Small molecule immunotherapy [183]
Cyclic compound 2 DMGRBAJ Patented Small molecule immunotherapy [183]
Cyclic compound 3 DMVOEN7 Patented Small molecule immunotherapy [183]
Cyclic peptidomimetic derivative 1 DMV2UQ5 Patented Small molecule immunotherapy [183]
Cyclic peptidomimetic derivative 2 DMWH3FP Patented Small molecule immunotherapy [183]
Cyclic peptidomimetic derivative 3 DMI7KG4 Patented Small molecule immunotherapy [183]
Macrocycle derivative 1 DMN7I9C Patented Small molecule immunotherapy [183]
Macrocycle derivative 2 DM5OEQZ Patented Small molecule immunotherapy [183]
Macrocycle derivative 3 DMYGFTI Patented Small molecule immunotherapy [183]
Macrocycle derivative 4 DMOQBN4 Patented Small molecule immunotherapy [183]
Macrocycle derivative 5 DMK3UJY Patented Small molecule immunotherapy [183]
Macrocycle derivative 6 DMQ84KW Patented Small molecule immunotherapy [183]
Macrocycle derivative 7 DMP2JF0 Patented Small molecule immunotherapy [183]
Macrocycle derivative 8 DMOMTBE Patented Small molecule immunotherapy [183]
Macrocycle derivative 9 DMARU0E Patented Small molecule immunotherapy [183]
Macrocyclic peptide analog 1 DMS65IT Patented Small molecule immunotherapy [183]
Macrocyclic peptide analog 2 DMOGLBZ Patented Small molecule immunotherapy [183]
Macrocyclic peptide analog 3 DMV172W Patented Small molecule immunotherapy [183]
N-phenyl-pyridine-2-carboxamide derivative 1 DMMDYAV Patented Small molecule immunotherapy [183]
N-phenyl-pyridine-2-carboxamide derivative 2 DM6OG2Y Patented Small molecule immunotherapy [183]
Peptide analog 1 DMF3LIX Patented Peptide [183]
Peptide analog 2 DMYFUM6 Patented Peptide [183]
Peptide analog 3 DMYMJV3 Patented Peptide [183]
Peptide analog 4 DM5KEVG Patented Peptide [183]
Peptide analog 5 DM8B13I Patented Peptide [183]
Peptide analog 6 DM68M0G Patented Peptide [183]
Phenylate derivative 1 DMEO9QB Patented Small molecule immunotherapy [183]
Phenylate derivative 2 DMG0ZSY Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example1 DMY37VQ Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example11 DMD65GU Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example12 DMN2K10 Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example13 DM4CN9K Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example14 DMAUFS7 Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example15 DMYHQ0S Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example16 DM6EKIV Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example2 DM9HMB4 Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example3 DMDCN43 Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example4 DMRKLTE Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example41 DMQPIK4 Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example42 DM95FIN Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example43 DMJSH0F Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example44 DM8KAIY Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example45 DMC075A Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example46 DMYFSAD Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example47 DM1TCBQ Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example48 DMH57FG Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example49 DM4D1WK Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example50 DMV15GM Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example51 DM08CBJ Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example52 DMJ1C0A Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example53 DM39FDV Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example54 DM9DL1E Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example57 DMZXC0D Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example58 DM3AY9K Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example59 DM6XWL9 Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example60 DMUZ85A Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example7 DMS42KH Patented Small molecule immunotherapy [183]
PMID30107136-Compound-Example8 DMBIK28 Patented Small molecule immunotherapy [183]
------------------------------------------------------------------------------------
⏷ Show the Full List of 84 Drug(s)
This Disease is Treated as An Indication in 98 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Dextrin-2-sulphate DM9APK1 Discontinued in Phase 3 NA [184]
HIV-IG DM62SM5 Discontinued in Phase 3 NA [185]
IR-103 DM7SA9J Discontinued in Phase 3 Vaccine [186]
VGV-1 DMTSYVW Discontinued in Phase 3 NA [187]
AZT-P-DDI DM04CIK Discontinued in Phase 2 Small molecular drug [188]
BMS-488043 DMRPU10 Discontinued in Phase 2 Small molecular drug [189]
BRECANAVIR DMRVH2S Discontinued in Phase 2 Small molecular drug [190]
DMP-961 DMI5XKC Discontinued in Phase 2 Small molecular drug [191]
Elvucitabine DMM5WQL Discontinued in Phase 2 Small molecular drug [192]
FOZIVUDINE TIDOXIL DMUD0IN Discontinued in Phase 2 Small molecular drug [193]
FP-21399 DM76PKX Discontinued in Phase 2 NA [194]
Gallium maltolate DMX0Z51 Discontinued in Phase 2 Small molecular drug [195]
Glutathionarsenoxide DME2L12 Discontinued in Phase 2 NA [196]
GSK-732461 DMJ0ZB6 Discontinued in Phase 2 Vaccine [197]
HGP-30W DMHHBX2 Discontinued in Phase 2 NA [198]
HRG-214 DMDXAEC Discontinued in Phase 2 NA [199]
L-696229 DM54I8A Discontinued in Phase 2 Small molecular drug [200]
Lodenosine DMGZ3BF Discontinued in Phase 2 Small molecular drug [201]
Loviride DMD16VS Discontinued in Phase 2 Small molecular drug [202]
MK-944a DMOZUPB Discontinued in Phase 2 Small molecular drug [203]
Mozenavir DMLG7QB Discontinued in Phase 2 Small molecular drug [204]
Opaviraline DMP0ARJ Discontinued in Phase 2 Small molecular drug [205]
Pro 542 DMLOGR3 Discontinued in Phase 2 NA [206]
R-18893 DMGVRQ2 Discontinued in Phase 2 NA [207]
R-87366 DMRZI3C Discontinued in Phase 2 Small molecular drug [208]
SpirH DMCHP1X Discontinued in Phase 2 NA [209]
Telinavir DM8OWID Discontinued in Phase 2 Small molecular drug [210]
GPG DMYR7LO Discontinued in Phase 1/2 Small molecular drug [211]
GS-9005 DM7R126 Discontinued in Phase 1/2 NA [212]
MVA-BN HIV Polytope DMUEEL1 Discontinued in Phase 1/2 NA [213]
MVA-BN polytope HIV vaccine DM696SS Discontinued in Phase 1/2 NA [213]
A-80987 DMGEWQ7 Discontinued in Phase 1 Small molecular drug [214]
CGP-53437 DMF0O2H Discontinued in Phase 1 Small molecular drug [215]
DMP-851 DM412S9 Discontinued in Phase 1 Small molecular drug [216]
DPC-082 DMSOHR6 Discontinued in Phase 1 Small molecular drug [217]
DPC-681 DM5HAG0 Discontinued in Phase 1 Small molecular drug [218]
DPC-684 DMS19VG Discontinued in Phase 1 Small molecular drug [219]
GPI-2A DMGM48B Discontinued in Phase 1 NA [220]
GPs-0193 DMI74OY Discontinued in Phase 1 NA [221]
JTK-656 DMEADBG Discontinued in Phase 1 NA [222]
KNI-764 DM6LTRC Discontinued in Phase 1 Small molecular drug [223]
L-697639 DMBIR5P Discontinued in Phase 1 Small molecular drug [224]
LASINAVIR DMHEKIN Discontinued in Phase 1 Small molecular drug [225]
MPC-9055 DMCMNKV Discontinued in Phase 1 NA [226]
PA-1050040 DMF4KPM Discontinued in Phase 1 NA [227]
PNU-142721 DMPWG2K Discontinued in Phase 1 Small molecular drug [228]
PRO-367 DMWESU9 Discontinued in Phase 1 NA [229]
R-82150 DMTK3DR Discontinued in Phase 1 Small molecular drug [230]
R-82913 DM4WJHY Discontinued in Phase 1 Small molecular drug [231]
R-944 DMJ2ZVW Discontinued in Phase 1 NA [232]
SCH-C DM8J9SF Discontinued in Phase 1 Small molecular drug [233]
SPI-256 DMKGL2I Discontinued in Phase 1 NA [234]
TBC-Thai DMOIOJY Discontinued in Phase 1 NA [235]
TRI-1144 DMOJFXS Discontinued in Phase 1 NA [236]
U-103017 DMTVC3W Discontinued in Phase 1 Small molecular drug [237]
U-96988 DML73BR Discontinued in Phase 1 Small molecular drug [238]
XM-323 DMQKH07 Discontinued in Phase 1 Small molecular drug [239]
AD-439 DMHQRJK Terminated NA [246]
AD-519 DMREAPY Terminated NA [247]
AG-1284 DMRI7YB Terminated Small molecular drug [248]
AG-1350 DMALV1W Terminated Small molecular drug [249]
AR177 DMHU1E8 Terminated Small molecular drug [250]
BAICALIN DMY1TLZ Terminated Small molecular drug [251]
BAY-793 DM69EHF Terminated NA [252]
BB-2275 DM6ETM8 Terminated NA [253]
BCH-371 DMZ0U39 Terminated Small molecular drug [254]
BL-1050 DMXQA0S Terminated NA [255]
BlockAide/CR DMTII1A Terminated NA [256]
BMS-182193 DMEDLHG Terminated NA [257]
CCR5Qb DMAZB1R Terminated Vaccine [258]
DMP-963 DMKU469 Terminated Small molecular drug [259]
DPC-A78277 DM67VDK Terminated NA [260]
Droxinavir hydrochloride DM6EJVF Terminated NA [261]
EM-2487 DMG9R8E Terminated Small molecular drug [262]
GE-20372A DMGM3VP Terminated NA [263]
GS-2992 DMPSZR0 Terminated NA [264]
GS-9148 DMCYZL3 Terminated Small molecular drug [265]
GS-9160 DMQSMB1 Terminated Small molecular drug [266]
HIV vaccine DMPNTWM Terminated NA [267]
ImmStat DM1MJKK Terminated NA [268]
ImmuDyn DMC264Q Terminated NA [269]
ISIS-5320 DMX3VRO Terminated NA [270]
KNI-102 DMXZNB2 Terminated Small molecular drug [271]
KRH-2731 DM2L0VF Terminated NA [272]
MIV-170 DMT9QB5 Terminated Small molecular drug [273]
MPI-461359 DMAVD4Q Terminated NA [274]
MSC-204 DMNYLEU Terminated Small molecular drug [275]
Navuridine DM8FB6E Terminated Small molecular drug [276]
Palinavir DMLKQUR Terminated Small molecular drug [277]
PF-4194471 DMHF8R1 Terminated NA [278]
RDEA-427 DM08BUV Terminated NA [279]
RDEA-640 DM61RGQ Terminated NA [279]
RP-400C DM0NB7C Terminated NA [280]
RP135 DMGYTVB Terminated NA [280]
SPD-756 DM9HFV7 Terminated Small molecular drug [281]
U-75875 DMRBXEA Terminated Small molecular drug [282]
UC-38 DM0Z7PK Terminated Small molecular drug [283]
UC-84 DMY9UEZ Terminated Small molecular drug [284]
------------------------------------------------------------------------------------
⏷ Show the Full List of 98 Drug(s)
This Disease is Treated as An Indication in 5 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Cytolin DMV8APG Preclinical Antibody [240]
ML SA1 DMOBPRI Preclinical Small molecular drug [242]
PA-161 DME5O4M Preclinical NA [243]
PD-176931 DMLQYEB Preclinical Small molecular drug [244]
PF-821385 DMNZG8T Preclinical NA [245]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 1 Preclinical Drugs
Drug Name Drug ID Highest Status Drug Type REF
Griffithsin DMNZA4L Preclinical Protein/peptide drug [241]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 67 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Anti-CCR5 mabs DMB45DW Investigative Monoclonal antibody [29]
Anti-HIV peptides DMJG31R Investigative NA [29]
Argotom-VAX DM38GGB Investigative NA [29]
BA-011 DMC1TI7 Investigative NA [29]
BMS-707035 DMFIFTM Investigative Small molecular drug [29]
CB-1922 DMSFXZU Investigative NA [285]
CBI-009 DMVN5AF Investigative NA [29]
CIGB-200 DM0ORSF Investigative NA [29]
CXCR4 gene disrupted T cells DMNSUD9 Investigative NA [286]
DABO-1047 DM00180 Investigative NA [29]
Dicaffeoylquinic acids DM4I5Z3 Investigative NA [287]
Dicaffeoyltartaric acids DMAV0BX Investigative NA [287]
EradicAide DM4AP4O Investigative NA [29]
ET-004 DMPS8QX Investigative NA [29]
ETV-002 DMSJQ8B Investigative NA [29]
Galactofucan sulphate fraction DM4SVYK Investigative NA [29]
GenePro DMJC810 Investigative NA [29]
GS-8374 DMELUQV Investigative NA [29]
HIV-LAMP-vax DMWHUNB Investigative NA [29]
HIV-PV DME4ZAX Investigative NA [29]
HIV-specific STAR fusions DMW1L5X Investigative NA [29]
HIVAX-2 DMG2AY2 Investigative NA [29]
HiviCides I and II DMUX9OF Investigative NA [29]
HS-HIV DMHBY03 Investigative NA [29]
IDX-15971 DMGUGIB Investigative NA [29]
IMC-HIV DMZ6ZMW Investigative NA [29]
IMM-252 DMFFD5T Investigative NA [29]
INDOPY-1 DMR3563 Investigative Small molecular drug [29]
INH-001 DM05KP0 Investigative NA [29]
INT-2500 DM1UMWF Investigative NA [29]
IQP-0528 DMQRK9J Investigative NA [29]
ITV-2 DMNCFPU Investigative NA [29]
ITV-3 DMBHVN7 Investigative NA [29]
ITV-4 DM6Q113 Investigative NA [29]
Ledgins DMZ231F Investigative NA [29]
Mapp-66 DMH8OOX Investigative NA [29]
MK-0536 DMH36FB Investigative NA [29]
MK-1107 DM5JX0R Investigative Small molecular drug [29]
Modified CCR5-transduced autologous hematopoietic stem cells DMGZ2PN Investigative NA [29]
NB-325 DM7K36E Investigative Small molecular drug [286]
ND-401 DMT0NQS Investigative NA [286]
NKTR-140 DMPVIED Investigative NA [29]
Nnrti DM6DB8H Investigative NA [29]
NNRTIs DM9R3QH Investigative NA [29]
Nrti DM4UVOQ Investigative NA [29]
NSC-625487 DM63G4R Investigative Small molecular drug [288]
OBP-AI2 DMW1XRF Investigative NA [29]
PAV-611 DMTA1J7 Investigative NA [29]
PROSTRATIN DM1HMJ5 Investigative Small molecular drug [289]
ProVax DMKYONS Investigative NA [29]
Q-101 DMTIU0X Investigative NA [29]
Q-102 DM8OGWD Investigative Small molecular drug [29]
R-1206 DMQEKOM Investigative NA [29]
RAP-102 DMWU5HS Investigative NA [29]
RBT-05 DM102U8 Investigative NA [29]
Rh-MBL DMAT9UI Investigative NA [29]
RO-1752 DMJZRJK Investigative NA [29]
SCY-644 DMJIMSY Investigative NA [29]
SE RNA DMYSKI0 Investigative Aptamer [290]
SNX-2 DMH5XJL Investigative NA [29]
SP-03 DM05FQR Investigative NA [29]
SP-10 DMRC2FF Investigative Small molecular drug [29]
Tat Oyi-Cys22 DMY8JKR Investigative NA [29]
TMB-358 DM5YKJ7 Investigative NA [29]
Tnk-6123 DMB4X03 Investigative NA [29]
VGV-X DMXJOUQ Investigative NA [29]
Virapt DMZAOOT Investigative NA [29]
------------------------------------------------------------------------------------
⏷ Show the Full List of 67 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Abacavir (marketed as Ziagen) and Abacavir-containing Medications. FDA. 2008.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 204060.
4 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
5 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7535).
7 Approved antiretroviral drugs. Antiretroviral Drugs. Company report of AVERT. 2009.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4833).
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7365).
10 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
11 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
12 Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect a... J Virol. 2009 Aug;83(16):7862-72.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2020
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6737).
15 ClinicalTrials.gov (NCT01565850) Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults. U.S. National Institutes of Health.
16 Clinical pipeline report, company report or official report of GlaxoSmithKline.
17 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006022)
18 ClinicalTrials.gov (NCT00568958) Naltrexone for Heavy Drinking in Young Adults. U.S. National Institutes of Health.
19 ClinicalTrials.gov (NCT04150068) Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA). U.S. National Institutes of Health.
20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 806).
21 Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd). Biochem Biophys Res Commun. 2009 Feb 13;379(3):775-9.
22 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1639).
23 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
24 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
25 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4813).
26 Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. Antivir Chem Chemother. 2009;19(4):165-76.
27 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4828).
28 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4825).
29 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
30 ClinicalTrials.gov (NCT00006327) Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand. U.S. National Institutes of Health.
31 ClinicalTrials.gov (NCT02369965) Test Albuvirtide in Experienced Patients. U.S. National Institutes of Health.
32 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8580).
33 ClinicalTrials.gov (NCT00686270) A Long Term Safety Study of Apricitabine in HIV-infected Patients. U.S. National Institutes of Health.
34 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3500).
35 ClinicalTrials.gov (NCT02951052) Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults. U.S. National Institutes of Health.
36 ClinicalTrials.gov (NCT00616928) Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged 8 Years. U.S. National Institutes of Health.
37 ClinicalTrials.gov (NCT04776252) Open-label, Follow-up of Doravirine/Islatravir for Participants With Human Immunodeficiency Virus -1 (HIV-1) Infection (MK-8591A-033). U.S. National Institutes of Health.
38 ClinicalTrials.gov (NCT00213083) Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission. U.S. National Institutes of Health.
39 ClinicalTrials.gov (NCT00001338) A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer. U.S. National Institutes of Health.
40 ClinicalTrials.gov (NCT01913353) A Non-inferiority Trial to Compare MVA-BN Smallpox Vaccine to ACAM2000. U.S. National Institutes of Health.
41 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
42 ClinicalTrials.gov (NCT00262106) Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection. U.S. National Institutes of Health.
43 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
44 ClinicalTrials.gov (NCT02151448) alphaDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies. U.S. National Institutes of Health.
45 ClinicalTrials.gov (NCT00005869) Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
46 The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance. J Antimicrob Chemother. 2014 Oct;69(10):2759-69.
47 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003716)
48 ClinicalTrials.gov (NCT03964415) A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (MOSAICO). U.S. National Institutes of Health.
49 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 807).
50 ClinicalTrials.gov (NCT02968849) Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (HVTN702). U.S. National Institutes of Health.
51 ClinicalTrials.gov (NCT02489461) Efficacy, Safety and Optimal Dose Selection VM-1500 in Comparison to Efavirenz When Added to Standard-of-care Antiretroviral Therapy.
52 Clinical pipeline report, company report or official report of Incyte.
53 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 607).
54 ClinicalTrials.gov (NCT00967187) Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.. U.S. National Institutes of Health.
55 ClinicalTrials.gov (NCT00294372) Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients. U.S. National Institutes of Health.
56 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 801).
57 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4999).
58 Narhex Life Sciences Limited announced a successful capital raising via a combined Rights Issue and Placement offering. 21 May 2007.
59 ClinicalTrials.gov (NCT00002413) A Study of MKC-442 in HIV-Positive Patients. U.S. National Institutes of Health.
60 ClinicalTrials.gov (NCT01218113) Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naive HIV-1 Infected Persons. U.S. National Institutes of Health.
61 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019124)
62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018372)
63 ClinicalTrials.gov (NCT00979771) A Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Rheumatoid Arthritis Patients. U.S. National Institutes of Health.
64 ClinicalTrials.gov (NCT03784079) A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults. U.S. National Institutes of Health.
65 Clinical pipeline report, company report or official report of FIT Biotech.
66 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009588)
67 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
68 Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine. PLoS One. 2012;7(11):e50397.
69 ClinicalTrials.gov (NCT01881581) Safety and Immunogenicity of Recombinant HIV Vaccines for HIV/AIDS. U.S. National Institutes of Health.
70 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005689)
71 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027243)
72 ClinicalTrials.gov (NCT00079794) Iscar for Supplemental Care in Stage IV Lung Cancer. U.S. National Institutes of Health.
73 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036741)
74 Metabolic Characterization of a Tripeptide Human Immunodeficiency Virus Type 1 Protease Inhibitor, KNI-272, in Rat Liver Microsomes. Antimicrob Agents Chemother. 1999 March; 43(3): 549-556.
75 ClinicalTrials.gov (NCT00504452) Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients. U.S. National Institutes of Health.
76 A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N Engl J Med. 1993 Oct 7;329(15):1065-72.
77 ClinicalTrials.gov (NCT01254656) A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022. U.S. National Institutes of Health.
78 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018409)
79 ClinicalTrials.gov (NCT01492985) Lipopeptide Immunisation With GTU-multiHIV Trial. U.S. National Institutes of Health.
80 ClinicalTrials.gov (NCT00251537) A Pilot Study of LTB4 in HIV-1 Infected Adults in LTB4 Sweden AB.
81 ClinicalTrials.gov (NCT00820846) Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults. U.S. National Institutes of Health.
82 ClinicalTrials.gov (NCT01058512) A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy. U.S. National Institutes of Health.
83 An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). J Med Chem. 2011 Jan 13;54(1):67-77.
84 ClinicalTrials.gov (NCT01105403) Exploratory Study on POL6326 in Stem Cell Mobilization. U.S. National Institutes of Health.
85 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023704)
86 ClinicalTrials.gov (NCT00002338) The Safety and Effectiveness of 935U83 in HIV-Infected Patients. U.S. National Institutes of Health.
87 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036934)
88 ClinicalTrials.gov (NCT00667017) RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
89 ClinicalTrials.gov (NCT00002314) A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma. U.S. National Institutes of Health.
90 ClinicalTrials.gov (NCT00046332) A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients. U.S. National Institutes of Health.
91 ClinicalTrials.gov (NCT00398125) Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults. U.S. National Institutes of Health.
92 ClinicalTrials.gov (NCT00888446) Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid. U.S. National Institutes of Health.
93 ClinicalTrials.gov (NCT00838162) A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients. U.S. National Institutes of Health.
94 ClinicalTrials.gov (NCT00966238) Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age. U.S. National Institutes of Health.
95 ClinicalTrials.gov (NCT05291520) A Phase 1, Open-Label, Single-Dose Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, GSK3810109, Administered Either Subcutaneously or Intravenously With Recombinant Human Hyaluronidase PH20 (rHuPH20) to Healthy Adults. U.S.National Institutes of Health.
96 ClinicalTrials.gov (NCT00498056) Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa. U.S. National Institutes of Health.
97 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031270)
98 ClinicalTrials.gov (NCT02099994) Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan Adults. U.S. National Institutes of Health.
99 HIV Plus - 8. 2006. Page(10).
100 Phase I/II Clinical Trials Using Gene-Modified Adult Hematopoietic Stem Cells for HIV: Lessons Learnt. Stem Cells Int. 2011;2011:393698.
101 Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
102 Clinical pipeline report, company report or official report of Benitec Ltd.
103 Clinical pipeline report, company report or official report of Virax Holdings Ltd.
104 ClinicalTrials.gov (NCT01058343) Safety of IFNa Kinoid in Systemic Lupus Erythematosus. U.S. National Institutes of Health.
105 ClinicalTrials.gov (NCT00858793) High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT. U.S. National Institutes of Health.
106 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016684)
107 ClinicalTrials.gov (NCT03606213) Therapeutic Vaccination in Treated HIV Disease. U.S. National Institutes of Health.
108 ClinicalTrials.gov (NCT00048217) A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102. U.S. National Institutes of Health.
109 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019994)
110 ClinicalTrials.gov (NCT01627678) Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART. U.S. National Institutes of Health.
111 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010310)
112 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032088)
113 Why have ten or so nontoxic, retrovirus integrase inhibitors not been made available for AIDS treatment. Biomed Pharmacother. 1999 Dec;53(10):484-6.
114 ClinicalTrials.gov (NCT00618605) Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults. U.S. National Institutes of Health.
115 ClinicalTrials.gov (NCT01496989) Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers. U.S. National Institutes of Health.
116 ClinicalTrials.gov (NCT00902824) Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine. U.S. National Institutes of Health.
117 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032413)
118 ClinicalTrials.gov (NCT00000753) A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC. U.S. National Institutes of Health.
119 Antiretroviral drugs in development. A report from HIV DART 2008: Frontiers in Drug Development for Antiretroviral Therapies, 9-12 December 2008, Rio Grande, Puerto Rico. Expert Opin Investig Drugs. 2009 Apr;18(4):549-53.
120 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017123)
121 Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor. Antimicrob Agents Chemother. 2014 Jun;58(6):3233-44.
122 Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties. J Med Chem. 2012 Nov 26;55(22):9492-509.
123 ClinicalTrials.gov (NCT00002214) Phase I Trial of S-1153 in Patients With HIV Infection. U.S. National Institutes of Health.
124 CCR5 Monoclonal Antibodies for HIV-1 Therapy. Curr Opin HIV AIDS. 2009 March; 4(2): 104-111.
125 ClinicalTrials.gov (NCT01080820) A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers. U.S. National Institutes of Health.
126 ClinicalTrials.gov (NCT01285141) Reactogenicity and Immunogenicity of Cervico-vaginal CN54gp140-hsp70 Conjugate Vaccine. U.S. National Institutes of Health.
127 ClinicalTrials.gov (NCT03984812) Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study. U.S. National Institutes of Health.
128 ClinicalTrials.gov (NCT01458769) Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz. U.S. National Institutes of Health.
129 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025833)
130 Clinical pipeline report, company report or official report of EuroVacc.
131 Clinical pipeline report, company report or official report of GeoVax.
132 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018879)
133 ClinicalTrials.gov (NCT02289482) A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects. U.S. National Institutes of Health.
134 Clinical pipeline report, company report or official report of Gilead Sciences.
135 ClinicalTrials.gov (NCT00532974) A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART). U.S. National Institutes of Health.
136 ClinicalTrials.gov (NCT01084343) Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects. U.S. National Institutes of Health.
137 ClinicalTrials.gov (NCT04811040) Study to Evaluate the Safety and Efficacy of GS-5423 and GS-2872 in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection. U.S. National Institutes of Health.
138 ClinicalTrials.gov (NCT00090077) Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults. U.S. National Institutes of Health.
139 ClinicalTrials.gov (NCT00741806) Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults. U.S. National Institutes of Health.
140 Clinical pipeline report, company report or official report of Profectus biosciences.
141 Clinical pipeline report, company report or official report of GeoVax.
142 ClinicalTrials.gov (NCT00117429) Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART). U.S. National Institutes of Health.
143 Clinical pipeline report, company report or official report of St Georges University of London.
144 Clinical pipeline report, company report or official report of Institut Pasteur.
145 ClinicalTrials.gov (NCT02218125) A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults. U.S. National Institutes of Health.
146 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025519)
147 ClinicalTrials.gov (NCT01348516) Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023. U.S. National Institutes of Health.
148 ClinicalTrials.gov (NCT02115919) Safety Study of Multikine in the Treatment of Perianal Warts. U.S. National Institutes of Health.
149 ClinicalTrials.gov (NCT00412477) A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine LFn-p24 Administered by the Intramuscular (IM) Route in Healthy Adults. U.S. National Institutes of Health.
150 ClinicalTrials.gov (NCT00121121) Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers. U.S. National Institutes of Health.
151 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024622)
152 ClinicalTrials.gov (NCT01152255) MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2). U.S. National Institutes of Health.
153 ClinicalTrials.gov (NCT00894114) A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019). U.S. National Institutes of Health.
154 Clinical pipeline report, company report or official report of Moderna
155 ClinicalTrials.gov (NCT02033109) Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use. U.S. National Institutes of Health.
156 ClinicalTrials.gov (NCT00187044) Evaluation of the Safety of a Polyvalent Virus in Healthy Adults. U.S. National Institutes of Health.
157 ClinicalTrials.gov (NCT04808908) Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease. U.S. National Institutes of Health.
158 Clinical pipeline report, company report or official report of Profectus biosciences.
159 Clinical pipeline report, company report or official report of Inovio Pharmaceuticals.
160 ClinicalTrials.gov (NCT00775424) PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection. U.S. National Institutes of Health.
161 ClinicalTrials.gov (NCT01260727) Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults. U.S. National Institutes ofHealth.
162 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030714)
163 ClinicalTrials.gov (NCT01045317) A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body. U.S. National Institutes of Health.
164 ClinicalTrials.gov (NCT00529698) Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein. U.S. National Institutes of Health.
165 Attenuation of Recombinant Vesicular Stomatitis Virus-Human Immunodeficiency Virus Type 1 Vaccine Vectors by Gene Translocations and G Gene Truncation Reduces Neurovirulence and Enhances Immunogenicity in Mice. J. Virol. January 2008 vol. 82 no. 1 207-219.
166 Clinical pipeline report, company report or official report of Shionogi (2011).
167 ClinicalTrials.gov (NCT04147715) Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults. U.S. National Institutes of Health.
168 ClinicalTrials.gov (NCT03705169) Pharmacokinetics of SAR441236. U.S. National Institutes of Health.
169 ClinicalTrials.gov (NCT00002363) The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients. U.S. National Institutes of Health.
170 Tapping into combination pills for HIV. Nat Rev Drug Discov. 2009 Jun;8(6):439-40.
171 ClinicalTrials.gov (NCT01577537) A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis. U.S. National Institutes of Health.
172 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002628)
173 ClinicalTrials.gov (NCT00441909) Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide. U.S. National Institutes of Health.
174 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026081)
175 The Continuing Evolution of HIV-1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets. Mol Biol Int. 2012;2012:401965.
176 ClinicalTrials.gov (NCT04493684) A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK3739937 in Healthy Participants. U.S.National Institutes of Health.
177 ClinicalTrials.gov (NCT05163522) A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Administered VH4004280 in Healthy Participants. U.S.National Institutes of Health.
178 ClinicalTrials.gov (NCT05393271) A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Administered VH4011499 in Healthy Participants. U.S.National Institutes of Health.
179 ClinicalTrials.gov (NCT05631704) A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled Randomized, Single and Multiple Ascending Dose First-Time-in-Human Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity. U.S.National Institutes of Health.
180 ClinicalTrials.gov (NCT00472719) Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults. U.S. National Institutes of Health.
181 ClinicalTrials.gov (NCT00016692) Safety and Tolerability of Z-100 in Patients With Early HIV Infection. U.S. National Institutes of Health.
182 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
183 A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
184 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006469)
185 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001803)
186 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019204)
187 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017048)
188 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005869)
189 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020278)
190 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016864)
191 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011150)
192 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007421)
193 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007452)
194 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005389)
195 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014315)
196 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014863)
197 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027409)
198 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002132)
199 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007914)
200 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001460)
201 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005453)
202 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002631)
203 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013179)
204 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004305)
205 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011603)
206 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005801)
207 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002204)
208 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008914)
209 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027201)
210 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003330)
211 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021646)
212 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018518)
213 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014935)
214 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002482)
215 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002438)
216 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008536)
217 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014106)
218 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014480)
219 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014481)
220 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008923)
221 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005972)
222 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030601)
223 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010459)
224 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002199)
225 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006772)
226 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027745)
227 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025464)
228 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010327)
229 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008881)
230 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002478)
231 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001064)
232 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017230)
233 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 804).
234 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023938)
235 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008804)
236 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016114)
237 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006008)
238 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004387)
239 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002483)
240 Clinical pipeline report, company report or official report of CytoDyn Inc.
241 ClinicalTrials.gov (NCT02875119) Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women
242 Activation of TRPML1 clears intraneuronal A in preclinical models of HIV infection. J Neurosci. 2014 Aug 20;34(34):11485-503.
243 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013765)
244 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010851)
245 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023943)
246 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002197)
247 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005760)
248 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005055)
249 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004154)
250 Anti-HIV-1 agent AR-177 blocks HIV integrase. AIDS Patient Care STDS. 1996 Feb;10(1):48-9.
251 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007921)
252 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002843)
253 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003251)
254 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005386)
255 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021965)
256 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017591)
257 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002890)
258 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021743)
259 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011151)
260 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020281)
261 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004768)
262 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012852)
263 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005311)
264 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005194)
265 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016343)
266 Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother. 2009 Mar;53(3):1194-203.
267 Clinical pipeline report, company report or official report of Crucell.
268 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009665)
269 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010167)
270 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003009)
271 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002506)
272 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020279)
273 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019379)
274 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028566)
275 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009440)
276 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001006)
277 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005466)
278 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029094)
279 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024208)
280 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013159)
281 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013016)
282 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002095)
283 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005073)
284 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005397)
285 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626).
286 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
287 Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother. 1998 Jan;42(1):140-6.
288 Synthesis and biological activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles: non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. Antivir Chem Chemother. 1999 Jul;10(4):211-7.
289 A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
290 Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
291 Clinical pipeline report, company report or official report of Gilead.
292 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
293 Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection. Drugs. 2015 Apr;75(5):503-14.
294 ClinicalTrials.gov (NCT02105987) A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current AntiretroviralRegimen. U.S. National Institutes of Health.
295 ClinicalTrials.gov (NCT00043953) Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects. U.S. National Institutes of Health.
296 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031682)